Literature DB >> 23361255

α-Synuclein and mitochondrial dysfunction in Parkinson's disease.

Stephen Mullin1, Anthony Schapira.   

Abstract

α-Synuclein (SNCA) is a substantive component of Lewy bodies, the pathological hallmark of Parkinson's disease (PD). The discovery and subsequent derivation of its role in PD has led to a suprising but fruitful convergence of the fields of biochemistry and molecular genetics. In particular, the manipulation of the cell lines of a number of forms of familial PD has implicated SNCA in distinct and diverse biochemical pathways related to its pathogenesis. This current and rapidly evolving concept indicates PD is a disease in which interacting pathways of oxidative stress, mitochondrial dysfunction and impaired regulation of protein turnover interact to cause dopaminergic cell dysfunction and death. SNCA has a central role in these processes and manipulation of its expression, degradation and aggregation appear to be promising neuroprotective therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23361255      PMCID: PMC4199090          DOI: 10.1007/s12035-013-8394-x

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  159 in total

Review 1.  Biogenesis of mitochondrial membrane proteins.

Authors:  Thomas Becker; Michael Gebert; Nikolaus Pfanner; Martin van der Laan
Journal:  Curr Opin Cell Biol       Date:  2009-05-05       Impact factor: 8.382

2.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

3.  alpha-Synuclein is phosphorylated in synucleinopathy lesions.

Authors:  Hideo Fujiwara; Masato Hasegawa; Naoshi Dohmae; Akiko Kawashima; Eliezer Masliah; Matthew S Goldberg; Jie Shen; Koji Takio; Takeshi Iwatsubo
Journal:  Nat Cell Biol       Date:  2002-02       Impact factor: 28.824

4.  Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi.

Authors:  Mohan K Sapru; Jonathan W Yates; Shea Hogan; Lixin Jiang; Jeremy Halter; Martha C Bohn
Journal:  Exp Neurol       Date:  2006-02-07       Impact factor: 5.330

5.  In vivo demonstration that alpha-synuclein oligomers are toxic.

Authors:  Beate Winner; Roberto Jappelli; Samir K Maji; Paula A Desplats; Leah Boyer; Stefan Aigner; Claudia Hetzer; Thomas Loher; Marçal Vilar; Silvia Campioni; Christos Tzitzilonis; Alice Soragni; Sebastian Jessberger; Helena Mira; Antonella Consiglio; Emiley Pham; Eliezer Masliah; Fred H Gage; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-15       Impact factor: 11.205

6.  Impairing the bioenergetic status and the biogenesis of mitochondria triggers mitophagy in yeast.

Authors:  M Priault; B Salin; J Schaeffer; F M Vallette; J-P di Rago; J-C Martinou
Journal:  Cell Death Differ       Date:  2005-06-10       Impact factor: 15.828

7.  Parkin mutations and susceptibility alleles in late-onset Parkinson's disease.

Authors:  Sofia A Oliveira; William K Scott; Eden R Martin; Martha A Nance; Ray L Watts; Jean P Hubble; William C Koller; Rajesh Pahwa; Matthew B Stern; Bradley C Hiner; William G Ondo; Fred H Allen; Burton L Scott; Christopher G Goetz; Gary W Small; Frank Mastaglia; Jeffrey M Stajich; Fengyu Zhang; Michael W Booze; Michelle P Winn; Lefkos T Middleton; Jonathan L Haines; Margaret A Pericak-Vance; Jeffery M Vance
Journal:  Ann Neurol       Date:  2003-05       Impact factor: 10.422

8.  Aging and the nigrostriatal dopamine system: a non-human primate study.

Authors:  I Irwin; L E DeLanney; T McNeill; P Chan; L S Forno; G M Murphy; D A Di Monte; M S Sandy; J W Langston
Journal:  Neurodegeneration       Date:  1994-12

9.  Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain.

Authors:  Latha Devi; Vijayendran Raghavendran; Badanavalu M Prabhu; Narayan G Avadhani; Hindupur K Anandatheerthavarada
Journal:  J Biol Chem       Date:  2008-02-01       Impact factor: 5.157

10.  Challenges to the development of disease-modifying therapies in Parkinson's disease.

Authors:  A H V Schapira
Journal:  Eur J Neurol       Date:  2011-03       Impact factor: 6.089

View more
  52 in total

Review 1.  The heterozygous A53T mutation in the alpha-synuclein gene in a Chinese Han patient with Parkinson disease: case report and literature review.

Authors:  Wei-Xi Xiong; Yi-Min Sun; Rong-Yuan Guan; Su-Shan Luo; Chen Chen; Yu An; Jian Wang; Jian-Jun Wu
Journal:  J Neurol       Date:  2016-07-08       Impact factor: 4.849

2.  Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress.

Authors:  Jaime N Guzman; Ema Ilijic; Ben Yang; Javier Sanchez-Padilla; David Wokosin; Dan Galtieri; Jyothisri Kondapalli; Paul T Schumacker; D James Surmeier
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

Review 3.  Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease.

Authors:  D James Surmeier; Glenda M Halliday; Tanya Simuni
Journal:  Exp Neurol       Date:  2017-08-02       Impact factor: 5.330

4.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

5.  Genetic deletion of the GATA1-regulated protein α-synuclein reduces oxidative stress and nitric oxide synthase levels in mature erythrocytes.

Authors:  Raffaele Renella; Julia S Schlehe; Dennis J Selkoe; David A Williams; Matthew J LaVoie
Journal:  Am J Hematol       Date:  2014-07-21       Impact factor: 10.047

6.  SIRT3 Acts as a Neuroprotective Agent in Rotenone-Induced Parkinson Cell Model.

Authors:  Jing-Yi Zhang; Yong-Ning Deng; Meng Zhang; Hua Su; Qiu-Min Qu
Journal:  Neurochem Res       Date:  2016-04-06       Impact factor: 3.996

Review 7.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

Review 8.  Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease.

Authors:  Fabio A Zucca; Juan Segura-Aguilar; Emanuele Ferrari; Patricia Muñoz; Irmgard Paris; David Sulzer; Tadeusz Sarna; Luigi Casella; Luigi Zecca
Journal:  Prog Neurobiol       Date:  2015-10-09       Impact factor: 11.685

9.  Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease.

Authors:  Andrea Herrera; Patricia Muñoz; Irmgard Paris; Gabriela Díaz-Veliz; Sergio Mora; Jose Inzunza; Kjell Hultenby; Cesar Cardenas; Fabián Jaña; Rita Raisman-Vozari; Katia Gysling; Jorge Abarca; Harry W M Steinbusch; Juan Segura-Aguilar
Journal:  Cell Mol Life Sci       Date:  2016-03-21       Impact factor: 9.261

Review 10.  Tumor necrosis factor receptor-associated periodic syndrome as a model linking autophagy and inflammation in protein aggregation diseases.

Authors:  Tiziana Bachetti; Isabella Ceccherini
Journal:  J Mol Med (Berl)       Date:  2014-04-06       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.